Pharmaceutical Contract Manufacturing Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
The Global Pharmaceutical Contract Manufacturing Market Size accounted for USD 135.6 Billion in 2022 and is projected to achieve a market size of USD 279.3 Billion by 2032 growing at a CAGR of 6.8% from 2023 to 2032.
Pharmaceutical Contract Manufacturing Market Report Key Highlights
- Global pharmaceutical contract manufacturing market revenue is expected to increase by USD 279.3 Billion by 2032, with a 6.8% CAGR from 2023 to 2032
- North America region led with more than 38% of pharmaceutical contract manufacturing market share in 2022
- Asia-Pacific region is expected to witness the highest growth rate due to the increasing demand for low-cost pharmaceutical products.
- The major CMOs in the pharmaceutical industry include Lonza, Catalent, Thermo Fisher Scientific, Patheon, and Pfizer CentreOne
- The COVID-19 pandemic has led to an increase in demand for contract manufacturing services for vaccines, treatments, and diagnostics
- Growing demand for biopharmaceuticals and biosimilars, drives the pharmaceutical contract manufacturing market size
Pharmaceutical Contract Manufacturing (PCM) is a type of outsourcing service where a pharmaceutical company hires a contract manufacturing organization (CMO) to produce drugs or drug components on its behalf. PCM allows pharmaceutical companies to save on costs and resources by partnering with specialized CMOs that have the necessary expertise, equipment, and facilities to produce high-quality drugs at a lower cost and faster turnaround time.
Pharmaceutical contract manufacturing contributes significantly to the overall outsourcing market, due to its acceptance and widespread implementation by pharmaceutical companies. Cost-cutting concerns stemming from global economic restraints have put great pressure on pharmaceutical makers to keep end-product costs under control. Pharmaceutical contract manufacturing is the division of goods production by outside firms under the brand of another firm, giving service to numerous manufacturers based on unique designs or specifications. Historically, the pharmaceutical sector required enterprises to be vertically integrated, i.e., the company itself performed all production processes; however, investors now want to sustain strong fiscal profitability, and as a result, outsourcing has emerged as a prominent means of doing business.
Global Pharmaceutical Contract Manufacturing Market Trends
Market Drivers
- Increasing demand for cost-effective drug production and rising healthcare expenditures
- Growing adoption of advanced technologies, such as biologics and cell and gene therapies
- Rise in outsourcing activities by pharmaceutical companies to focus on core competencies
- Growing demand for generic drugs due to expiration of patents
Market Restraints
- High initial investment costs for equipment and facilities
- Dependence on the quality and reliability of the CMOs
Market Opportunities
- Growing demand for biopharmaceuticals and biosimilars
- Increasing demand for clinical trial support services
Pharmaceutical Contract Manufacturing Market Report Coverage
| Market | Pharmaceutical Contract Manufacturing Market |
| Pharmaceutical Contract Manufacturing Market Size 2022 | USD 135.6 Billion |
| Pharmaceutical Contract Manufacturing Market Forecast 2032 | USD 279.3 Billion |
| Pharmaceutical Contract Manufacturing Market CAGR During 2023 - 2032 | 6.8% |
| Pharmaceutical Contract Manufacturing Market Analysis Period | 2020 - 2032 |
| Pharmaceutical Contract Manufacturing Market Base Year | 2022 |
| Pharmaceutical Contract Manufacturing Market Forecast Data | 2023 - 2032 |
| Segments Covered | By Services, By End-user, And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Lonza Group AG, Catalent, Inc., Thermo Fisher Scientific Inc., Patheon N.V., Evonik Industries AG, AbbVie Contract Manufacturing, Boehringer Ingelheim GmbH, Recipharm AB, Jubilant Life Sciences Limited, and Dr. Reddy's Laboratories Ltd. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
The pharmaceutical contract manufacturing market has been experiencing significant growth in recent years, and this trend is expected to continue in the coming years. Contract manufacturing organizations (CMOs) provide pharmaceutical companies with a range of services, including drug development, formulation, manufacturing, and packaging. These services help pharmaceutical companies to reduce their operational costs and focus on their core competencies, such as research and development.
One of the key drivers of growth in the pharmaceutical contract manufacturing market is the increasing demand for innovative medicines. Pharmaceutical companies are under pressure to develop new and more effective treatments for a range of diseases, and outsourcing to CMOs can help them to bring these products to market more quickly and cost-effectively. Additionally, the growing prevalence of chronic diseases, such as cancer and diabetes, is driving demand for pharmaceutical products, which is fueling growth in the contract manufacturing market.
Another factor driving the growth of the pharmaceutical contract manufacturing market is the increasing globalization of the pharmaceutical industry. Many pharmaceutical companies are looking to expand their operations into emerging markets, such as Asia and Latin America, to take advantage of lower manufacturing costs and growing demand for pharmaceutical products in these regions. CMOs with a global presence are well-positioned to meet the needs of these companies and help them to establish a presence in these markets. Overall, the pharmaceutical contract manufacturing market is poised for continued growth in the coming years, driven by increasing demand for innovative medicines and the globalization of the pharmaceutical industry.
Pharmaceutical Contract Manufacturing Market Segmentation
The global Pharmaceutical Contract Manufacturing market segmentation is based on Services, End-user, and geography.
Pharmaceutical Contract Manufacturing Market By Services
- Pharmaceutical Manufacturing Services
- Pharmaceutical FDF Manufacturing Services
- Tablet manufacturing services
- Parenteral/injectable manufacturing services
- Capsule manufacturing services
- Semi-solid manufacturing services
- Oral liquid manufacturing services
- Other formulation manufacturing services
- Pharmaceutical API Manufacturing Services
- Pharmaceutical FDF Manufacturing Services
- Biologics Manufacturing Services
- Biologics FDF Manufacturing Services
- Biologics API Manufacturing Services
- Drug Development Services
According to a pharmaceutical contract manufacturing industry analysis, the drug development services segment is expected to garner significant market focus in the coming years. This segment includes a range of services, such as formulation development, analytical testing, clinical trials, and regulatory support. Contract manufacturers work closely with pharmaceutical companies to develop and produce safe and effective drugs, ensuring compliance with regulatory requirements and industry standards. The increasing demand for cost-effective and efficient drug development services has led to significant growth in the pharmaceutical contract manufacturing market, with a focus on innovative technologies and streamlined processes. The market is highly competitive, with numerous contract manufacturing organizations offering specialized services to meet the diverse needs of pharmaceutical companies.
Pharmaceutical Contract Manufacturing Market By End-user
- Big Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Small & Medium-sized Pharmaceutical Companies
- Others
According to the pharmaceutical contract manufacturing market forecast, generic pharmaceutical companies would rise rapidly in the coming years. The market for generic pharmaceuticals has grown rapidly in recent years, driven by the increasing demand for affordable and accessible healthcare products. This has led to increased outsourcing of manufacturing services to contract manufacturers, who can provide specialized expertise and capabilities in areas such as formulation development, regulatory compliance, and quality control. The generic pharmaceutical contract manufacturing market is highly competitive, with a large number of contract manufacturers offering a range of services to meet the needs of generic drug companies.
Pharmaceutical Contract Manufacturing Market Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Geographically, North America is dominating the pharmaceutical contract manufacturing market. This growth is due to various factors such as the availability of skilled labor, established regulatory framework, and advanced technological infrastructure. The region is home to some of the world's leading pharmaceutical companies, which have long-standing relationships with contract manufacturers for the outsourcing of drug development and production services. Additionally, the United States is the largest pharmaceutical market globally, with a high demand for cost-effective and efficient drug development services. The growing focus on personalized medicine, biologics, and biosimilars has also contributed to the growth of the pharmaceutical contract manufacturing market in North America, with contract manufacturers offering specialized expertise in these areas.
Pharmaceutical Contract Manufacturing Market Player
Some of the top pharmaceutical contract manufacturing market companies offered in the professional report includes Lonza Group AG, Catalent, Inc., Thermo Fisher Scientific Inc., Patheon N.V., Evonik Industries AG, AbbVie Contract Manufacturing, Boehringer Ingelheim GmbH, Recipharm AB, Jubilant Life Sciences Limited, and Dr. Reddy's Laboratories Ltd.
Frequently Asked Questions
How big is the pharmaceutical contract manufacturing market?
The pharmaceutical contract manufacturing market size was USD 135.6 Billion in 2022.
What is the CAGR of the global pharmaceutical contract manufacturing market during forecast period of 2023 to 2032?
The CAGR of pharmaceutical contract manufacturing market is 6.8% during the analysis period of 2023 to 2032.
Which are the key players operating in the market?
The key players operating in the global pharmaceutical contract manufacturing market are Lonza Group AG, Catalent, Inc., Thermo Fisher Scientific Inc., Patheon N.V., Evonik Industries AG, AbbVie Contract Manufacturing, Boehringer Ingelheim GmbH, Recipharm AB, Jubilant Life Sciences Limited, and Dr. Reddy's Laboratories Ltd.
Which region held the dominating position in the global pharmaceutical contract manufacturing market?
North America held the dominating position in pharmaceutical contract manufacturing market during the analysis period of 2023 to 2032.
Which region registered the fastest growing CAGR for the forecast period of 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for pharmaceutical contract manufacturing market during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global pharmaceutical contract manufacturing market?
The current trends and dynamics in the pharmaceutical contract manufacturing industry include the increasing demand for cost-effective drug production and rising healthcare expenditures.
Which services held the maximum share in 2022?
The pharmaceutical manufacturing services held the maximum share of the pharmaceutical contract manufacturing market.
Select Licence Type
Connect with our sales team
Why Acumen Research and Consulting
100%
Customer Satisfaction
24x7+
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
